{"id":"abt450r-abt267-abt333-ribavirin","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABT450r is a boosted NS3/4A protease inhibitor, ABT267 is an NS5A inhibitor, and ABT333 is an NS5B non-nucleoside polymerase inhibitor. Together they target multiple steps of HCV replication. Ribavirin, when included, is a nucleoside analog that enhances viral suppression through additional mechanisms.","oneSentence":"This is a fixed-dose combination of three direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease, NS5A protein, and NS5B polymerase, with optional ribavirin co-administration.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:26:06.002Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, genotype 1"}]},"trialDetails":[{"nctId":"NCT02734173","phase":"PHASE4","title":"Pilot HCV Direct Acting Antiviral Therapy and Metabolism","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2015-07","conditions":"Hepatitis C","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15996,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin"],"phase":"marketed","status":"active","brandName":"ABT450r-ABT267-ABT333 +/- Ribavirin","genericName":"ABT450r-ABT267-ABT333 +/- Ribavirin","companyName":"Ottawa Hospital Research Institute","companyId":"ottawa-hospital-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination of three direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease, NS5A protein, and NS5B polymerase, with optional ribavirin co-administration. Used for Chronic hepatitis C virus (HCV) infection, genotype 1, Chronic hepatitis C virus (HCV) infection, treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}